Sage Therapeutics - SAGE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.47
  • Forecasted Upside: 26.76 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.15 (-0.35%)

This chart shows the closing price for SAGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

Analyst Price Target is $54.47
▲ +26.76% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $54.47, with a high forecast of $85.00 and a low forecast of $37.00. The average price target represents a 26.76% upside from the last price of $42.97.

This chart shows the closing price for SAGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 investment analysts is to hold stock in Sage Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 12 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2022CitigroupLower Target$41.00 ➝ $40.00Low
8/2/2022Stifel NicolausLower Target$58.00 ➝ $56.00Low
7/11/2022SVB LeerinkLower TargetMarket Perform$50.00 ➝ $40.00N/A
6/3/2022CitigroupBoost Target$41.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$85.00 ➝ $73.00High
5/4/2022MizuhoLower Target$41.00 ➝ $37.00High
3/31/2022Berenberg BankInitiated CoverageHold$37.00High
3/10/2022Morgan StanleyLower TargetEqual Weight$61.00 ➝ $57.00Low
3/9/2022Truist FinancialLower TargetHold$60.00 ➝ $40.00High
3/3/2022MizuhoLower TargetNeutral$44.00 ➝ $41.00Medium
2/25/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$95.00 ➝ $64.00High
2/25/2022SVB LeerinkLower TargetMarket Perform$60.00 ➝ $50.00High
2/17/2022The Goldman Sachs GroupLower TargetBuy$96.00High
1/6/2022Needham & Company LLCBoost TargetBuy$79.00 ➝ $85.00High
12/20/2021SVB LeerinkLower TargetMarket Perform$70.00 ➝ $60.00Low
11/18/2021Needham & Company LLCReiterated RatingBuy$78.00Low
11/18/2021MizuhoLower TargetNeutral$52.00 ➝ $44.00High
11/3/2021OppenheimerLower TargetOutperform$84.00 ➝ $80.00High
11/3/2021HC WainwrightLower TargetNeutral$80.00 ➝ $55.00High
11/2/2021Royal Bank of CanadaLower TargetSector Perform$52.00 ➝ $48.00High
11/2/2021GuggenheimUpgradeNeutral ➝ Buy$55.00High
10/20/2021Needham & Company LLCInitiated CoverageBuy$84.00 ➝ $80.00Low
10/20/2021OppenheimerLower TargetPositive ➝ Outperform$100.00 ➝ $84.00Low
10/18/2021SVB LeerinkReiterated RatingMarket PerformHigh
10/12/2021Morgan StanleyLower TargetEqual Weight$81.00 ➝ $78.00Low
10/7/2021SVB LeerinkReiterated RatingHoldLow
10/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$100.00 ➝ $50.00High
10/4/2021Stifel NicolausLower TargetBuy$95.00 ➝ $75.00High
9/22/2021Needham & Company LLCInitiated CoverageBuy$84.00High
8/4/2021Royal Bank of CanadaLower TargetSector Perform$60.00 ➝ $55.00Medium
8/4/2021HC WainwrightLower TargetNeutral$86.00 ➝ $80.00Medium
6/16/2021SVB LeerinkLower TargetMarket Perform$90.00 ➝ $70.00High
6/16/2021HC WainwrightReiterated RatingHoldHigh
6/16/2021Stifel NicolausLower TargetBuy$121.00 ➝ $95.00High
6/16/2021William BlairDowngradeOutperform ➝ Market Perform$62.00High
6/16/2021BMO Capital MarketsLower TargetPositive ➝ Market Perform$87.00 ➝ $73.00High
6/16/2021CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $68.00High
5/5/2021MizuhoLower TargetNeutral$81.00 ➝ $77.00Medium
4/19/2021Morgan StanleyLower TargetEqual Weight$87.00 ➝ $81.00Low
4/12/2021MizuhoReiterated RatingHold$81.00High
4/7/2021Piper SandlerInitiated CoverageOverweight$100.00Medium
3/4/2021MizuhoReiterated RatingBuy ➝ Neutral$81.00High
3/2/2021Morgan StanleyBoost TargetEqual Weight$83.00 ➝ $87.00High
2/26/2021MizuhoDowngradeBuy ➝ Neutral$81.00High
2/25/2021OppenheimerBoost TargetOutperform$90.00 ➝ $102.00Low
2/25/2021HC WainwrightBoost TargetNeutral$74.00 ➝ $86.00High
2/25/2021HC WainwrightReiterated RatingNeutral$74.00 ➝ $86.00High
2/1/2021Raymond JamesInitiated CoverageMarket PerformLow
1/22/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$95.00High
1/19/2021WedbushBoost TargetOutperform$83.00 ➝ $98.00Low
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
1/4/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$83.00 ➝ $86.00N/A
12/4/2020William BlairReiterated RatingBuyLow
12/4/2020MizuhoUpgradeNeutral ➝ Buy$77.00 ➝ $81.00Low
12/1/2020Truist FinancialBoost Target$60.00 ➝ $70.00Low
12/1/2020Smith Barney CitigroupLower Target$100.00 ➝ $93.00Low
12/1/2020Royal Bank of CanadaLower Target$86.00 ➝ $83.00Low
12/1/2020HC WainwrightLower TargetNeutral$81.00 ➝ $74.00Low
12/1/2020Morgan StanleyLower TargetEqual Weight$85.00 ➝ $83.00Low
11/30/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
11/19/2020OppenheimerBoost Target$65.00 ➝ $94.00Medium
11/16/2020Bank of AmericaBoost TargetBuy$72.00 ➝ $95.00High
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$87.00 ➝ $85.00High
11/10/2020Truist FinancialBoost TargetHold$35.00 ➝ $60.00Low
11/6/2020Smith Barney CitigroupBoost Target$67.00 ➝ $100.00Low
11/6/2020MizuhoBoost TargetNeutral$53.00 ➝ $77.00Medium
11/6/2020BMO Capital MarketsBoost TargetOutperform$79.00 ➝ $89.00Medium
11/6/2020HC WainwrightBoost TargetNeutral$76.00 ➝ $81.00Medium
10/20/2020Royal Bank of CanadaBoost TargetOutperform$75.00 ➝ $84.00Low
10/16/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$65.00 ➝ $79.00High
9/11/2020CitigroupBoost TargetPositive ➝ Buy$54.00 ➝ $67.00Low
9/11/2020WedbushUpgradeNeutral ➝ Outperform$40.00 ➝ $65.00Low
8/24/2020Morgan StanleyBoost TargetOverweight$85.00 ➝ $87.00Medium
8/11/2020Royal Bank of CanadaReiterated RatingBuyMedium
8/11/2020OppenheimerBoost TargetOutperform$50.00 ➝ $65.00High
8/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00Low
8/10/2020MizuhoReiterated RatingHold$44.00High
5/26/2020Royal Bank of CanadaBoost TargetOutperform$72.00 ➝ $75.00Low
5/8/2020SunTrust BanksLower TargetHold$37.00 ➝ $35.00High
5/8/2020Royal Bank of CanadaBoost TargetOutperform$71.00 ➝ $72.00High
5/8/2020WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $37.00Medium
5/8/2020MizuhoBoost TargetNeutral$36.00 ➝ $44.00Medium
4/28/2020Royal Bank of CanadaBoost TargetOutperform$68.00 ➝ $71.00High
4/19/2020GuggenheimDowngradeBuy ➝ NeutralHigh
4/9/2020BMO Capital MarketsLower TargetOutperform$86.00 ➝ $65.00Medium
4/9/2020SunTrust BanksLower TargetHold$40.00 ➝ $37.00Medium
4/8/2020Royal Bank of CanadaBoost TargetOutperform$60.00 ➝ $68.00High
4/8/2020WedbushLower TargetOutperform$56.00 ➝ $36.00High
4/8/2020OppenheimerLower TargetOutperform$60.00 ➝ $50.00High
4/8/2020CitigroupBoost TargetBuy$48.00 ➝ $54.00High
4/8/2020GuggenheimDowngradeBuy ➝ NeutralHigh
4/8/2020MizuhoLower TargetNeutral$58.00 ➝ $36.00High
3/26/2020SunTrust BanksLower TargetHold$50.00 ➝ $40.00Medium
3/22/2020HC WainwrightReiterated RatingHold$78.00Low
3/20/2020LADENBURG THALM/SH SHReiterated RatingHold$28.00High
3/19/2020OppenheimerLower Target$97.00 ➝ $60.00Low
3/19/2020SVB LeerinkBoost TargetMarket Perform$45.00 ➝ $63.00Low
3/19/2020GuggenheimLower TargetBuy$85.00 ➝ $65.00Low
3/19/2020CitigroupLower TargetBuy$71.00 ➝ $48.00Low
3/18/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$73.00 ➝ $60.00High
3/11/2020MizuhoReiterated RatingHold$58.00High
3/5/2020CitigroupInitiated CoverageBuy$71.00High
3/3/2020Morgan StanleyLower TargetOverweight$125.00 ➝ $117.00Medium
2/28/2020SunTrust BanksLower TargetHold$60.00 ➝ $50.00High
2/28/2020LADENBURG THALM/SH SHReiterated RatingHold$52.00High
2/28/2020HC WainwrightLower TargetNeutral$87.00 ➝ $78.00High
2/28/2020MizuhoLower TargetNeutral$69.00 ➝ $58.00High
2/27/2020CowenReiterated RatingBuy$96.00High
2/27/2020MizuhoReiterated RatingHold$69.00High
2/5/2020MizuhoInitiated CoverageNeutral$69.00Low
1/7/2020Bank of AmericaBoost Target$85.00 ➝ $98.00Medium
12/6/2019OppenheimerLower Target$190.00 ➝ $100.00Medium
12/6/2019JPMorgan Chase & Co.Lower TargetOverweight$200.00 ➝ $105.00Low
12/6/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
12/6/2019Royal Bank of CanadaLower TargetOutperform$190.00 ➝ $100.00High
12/6/2019Morgan StanleyLower TargetOverweight$217.00 ➝ $125.00High
12/6/2019BMO Capital MarketsReiterated RatingOutperform$92.00High
12/6/2019SVB LeerinkUpgradeUnderperform ➝ Market PerformHigh
12/6/2019HC WainwrightLower TargetNeutral$160.00 ➝ $87.00High
12/5/2019The Goldman Sachs GroupLower Target$227.00 ➝ $263.00High
12/5/2019Piper Jaffray CompaniesLower TargetOverweight$206.00 ➝ $125.00High
12/5/2019GuggenheimLower TargetBuy$200.00 ➝ $110.00High
12/5/2019CowenReiterated RatingBuy$96.00High
12/5/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$73.00High
12/5/2019WedbushLower TargetOutperform$203.00 ➝ $90.00High
12/5/2019SunTrust BanksDowngradeBuy ➝ Hold$210.00 ➝ $70.00High
11/25/2019Royal Bank of CanadaReiterated RatingBuy$235.00Low
11/24/2019Morgan StanleyReiterated RatingBuy$217.00Medium
11/20/2019Stifel NicolausReiterated RatingBuyLow
10/30/2019HC WainwrightInitiated CoverageNeutral$160.00Low
8/7/2019OppenheimerLower TargetOutperform$200.00 ➝ $190.00Medium
7/25/2019OppenheimerBoost Target$170.00 ➝ $200.00Medium
7/24/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
7/24/2019William BlairReiterated RatingBuyLow
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$207.00Low
5/5/2019OppenheimerSet TargetBuy$170.00Medium
5/2/2019LADENBURG THALM/SH SHSet TargetBuy$220.00Low
4/26/2019Raymond JamesReiterated RatingMarket PerformMedium
4/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$195.00Low
2/22/2019GuggenheimInitiated CoverageBuy$205.00High
12/19/2018Morgan StanleyLower TargetOverweight ➝ Overweight$230.00 ➝ $213.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/11/2018LADENBURG THALM/SH SHSet TargetBuy$210.00High
11/20/2018OppenheimerSet TargetBuy$170.00Low
11/12/2018SVB LeerinkInitiated CoverageUnderperform$80.00High
11/6/2018JPMorgan Chase & Co.Set TargetBuy$205.00Medium
11/5/2018Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$259.00 ➝ $261.00Medium
11/4/2018OppenheimerSet TargetBuy$170.00High
11/1/2018CowenReiterated RatingBuy$207.00High
10/31/2018LADENBURG THALM/SH SHSet TargetBuy$235.00High
10/29/2018OppenheimerSet TargetBuy$170.00High
10/17/2018OppenheimerInitiated CoverageBuy$170.00Medium
10/11/2018Morgan StanleyBoost TargetOverweight$228.00 ➝ $230.00High
10/10/2018OppenheimerInitiated CoverageBuy$170.00Low
8/7/2018Stifel NicolausBoost TargetBuy$198.00 ➝ $239.00Medium
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$206.00Medium
7/13/2018Morgan StanleyBoost TargetOverweight$225.00 ➝ $228.00Low
6/14/2018CowenReiterated RatingBuy$207.00Medium
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$230.00High
5/3/2018CowenReiterated RatingBuyLow
3/20/2018CowenReiterated RatingBuy$202.00Low
2/28/2018SunTrust BanksBoost TargetBuy$203.00Low
2/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$225.00Low
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00Low
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
12/11/2017CowenReiterated RatingBuyLow
12/8/2017Stifel NicolausReiterated RatingBuy$198.00Low
12/8/2017SunTrust BanksBoost TargetPositive$178.00High
12/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight$198.00High
12/7/2017Raymond JamesReiterated RatingBuy$206.00High
12/7/2017Needham & Company LLCBoost TargetBuy ➝ Buy$100.00 ➝ $193.00High
12/7/2017SVB LeerinkBoost Target$123.00 ➝ $246.00High
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00High
12/7/2017Royal Bank of CanadaBoost TargetOutperform ➝ Sell$137.00 ➝ $280.00High
11/27/2017Royal Bank of CanadaLower TargetOutperform$145.00 ➝ $137.00Medium
11/17/2017BMO Capital MarketsReiterated RatingOutperform$85.67 ➝ $112.00N/A
11/16/2017Bank of AmericaLower TargetBuy$103.00 ➝ $101.00N/A
11/15/2017SunTrust BanksBoost TargetBuy ➝ Positive$116.00N/A
11/10/2017Needham & Company LLCBoost TargetBuy ➝ Buy$86.00 ➝ $100.00N/A
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/A
11/9/2017Raymond JamesBoost TargetBuy$109.00N/A
11/9/2017Stifel NicolausBoost TargetBuy$91.00 ➝ $105.00N/A
11/9/2017Royal Bank of CanadaBoost TargetOutperform$145.00N/A
11/9/2017SVB LeerinkBoost TargetOutperform ➝ Positive$85.00 ➝ $123.00N/A
11/2/2017Royal Bank of CanadaBoost Target$117.00 ➝ $120.00N/A
10/27/2017BMO Capital MarketsReiterated RatingBuy$80.00N/A
10/19/2017SunTrust BanksSet TargetBuy$82.00N/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$117.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$87.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$117.00Medium
9/14/2017BMO Capital MarketsBoost TargetOutperform$80.00 ➝ $84.00High
9/13/2017Chardan CapitalReiterated RatingHoldHigh
9/13/2017Needham & Company LLCLower TargetBuy ➝ Buy$95.00 ➝ $86.00High
9/13/2017Stifel NicolausReiterated RatingBuy$104.00 ➝ $91.00High
9/13/2017SunTrust BanksReiterated RatingBuy$95.00 ➝ $82.00High
9/12/2017JPMorgan Chase & Co.Lower TargetOverweight$99.00 ➝ $85.00High
9/12/2017CowenLower TargetOutperform$100.00 ➝ $90.00Medium
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
(Data available from 8/19/2017 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
  • 3 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
  • 2 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Sage Therapeutics logo
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $42.97
Low: $41.62
High: $43.29

50 Day Range

MA: $36.06
Low: $31.36
High: $43.27

52 Week Range

Now: $42.97
Low: $27.36
High: $47.75


560,336 shs

Average Volume

507,283 shs

Market Capitalization

$2.55 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Berenberg Bank, Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus,, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Truist Financial Co..
View the latest analyst ratings for SAGE.

What is the current price target for Sage Therapeutics?

15 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $54.47, suggesting a possible upside of 26.8%. Needham & Company LLC has the highest price target set, predicting SAGE will reach $85.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $37.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 8 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SAGE, but not buy more shares or sell existing shares.
View the latest ratings for SAGE.

What other companies compete with Sage Therapeutics?

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 299-8380 and its investor relations email address is [email protected] The official website for Sage Therapeutics is Learn More about contacing Sage Therapeutics investor relations.